Digital Health Today | Insights from the innovator

Women and girls in low/middle-income countries are facing an urgent unmet need for modern contraception. This World Contraception Day, join guest host Sophie Park, Managing Director at G4A Digital Health Bayer in conversation with Dr. Ariane de Hoog, Lead Access to Medicine, Community Engagement at Bayer, and Titilola Olaolu-Hassan, Co-Founder & COO at Zuri Health, for this vital discussion on harnessing digital health solutions to empower women and enhance healthcare accessibility in Africa. Topics include: [00:02:14] Background to Bayer’s interest in empowering Women’s health. [00:05:05] Zuri Health: Affordable healthcare for underserved communities. [00:06:28] Impact goals behind Zuri becoming a G4A Portfolio company. [00:11:37] How the Zuri Health platform directly improves girls' and women's access to healthcare. [00:14:08] The future beyond family planning for Zuri Health in partnership with Bayer. [00:15:53] Bayer’s impact goal to provide 100 million women access to modern contraception by 2030. [00:20:23] Empowering women to make informed decisions irrespective of location Guest & Host Links Connect with Dan Kendall on LinkedIn Connect with Sophie Park on LinkedIn Connect with Dr. Ariane de Hoog on LinkedIn Connect with Titilola Olaolu-Hassan on LinkedIn Bayer G4A Zuri Health - Your-Life website - complimentary access to an array of educational and training resources on adolescent health and contraceptive counselling Digital Health Today would not be possible without the support of leading organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: LSI | Lindus Health | Bayer G4A Connect on Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Connect on Health Podcast Network: Browse Shows | Linkedin | Twitter | Facebook | Instagram

The Digital Medicine Society (DiMe) and Moffitt Cancer Center have announced they are co-hosting CancerX, a new public-private partnership effort to rapidly accelerate the pace of cancer innovation in the U.S. Alongside the Office of the National Coordinator for Health Information Technology (ONC) and the Office of the Assistant Secretary for Health (OASH), Moffitt Cancer Center and DiMe are urging the healthcare and digital health sectors to boost technology-driven initiatives to combat cancer. The two groups are working together to accelerate cancer research advancements, and they invite other organizations to do the same. The Biden administration's revived Cancer Moonshot includes the new CancerX public-private partnership. According to officials, the goal is to use industry collaboration and disruptive innovation to lessen the burden of cancer on everyone. The CancerX program will focus on using digital innovation to reduce disparities and financial toxicity in cancer care and research, working with government organizations, and will enlist industry parties to help with the mammoth undertaking. CancerX uniquely blends DiMe’s expertise in convening cross-disciplinary groups to develop clinical-quality resources on a tech timeline with Moffitt’s top research and care experts working side-by-side to revolutionize cancer treatment, extend access to the highest-quality care, and save more lives. The initiative is open to all those working in the field who are committed to working collaboratively and share a vision of unleashing the power of innovation to design and create a future that's free of the burden of cancer. Topics include: What is the Digital Medicine Society? Announcing CancerX, key initiatives and membership structure Improving the global ecosystem Guest & Host Links Connect with Dan Kendall | LinkedIn Connect with Jennifer Goldsack | LinkedIn and listen to her episode from May 2019 CancerX Digital Medicine Society Dime Academy DiMe Society Slack Digital Health Today would not be possible without the support of leading organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: Akili | Lindus Health | Bayer G4A Connect on Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Connect on Health Podcast Network: Browse Shows | Linkedin | Twitter | Facebook | Instagram

In this coffee talk with AmalgamRX we dive into the challenges being faced by health systems as they work to assess, develop, and implement solutions at the time of a clinical decision. We'll explore the major pain points that keep projects from reaching their full potential, what it takes to overcome these challenges and what you can do when you're developing a digital therapeutic solution for your organization. There's also some tips that apply to payers and pharma as they play a key role in the successful development and implementation of digital therapies. Guest Links and Resources: Connect with Jenni Main on LinkedIn Connect with Dr. Suzanne Clough on LinkedIn Visit https://amalgamrx.com/ Host Links: Connect with Dan Kendall: Twitter | LinkedIn Connect with Eugene Borukhovich: Twitter | LinkedIn Connect on Digital Health Today: Browse Episodes | Twitter | Linkedin | Facebook | Instagram Connect on Health Podcast Network: Browse Shows | Linkedin | Twitter | Facebook | Instagram

I’m glad to be back on the mic and bringing you this special episode of Digital Health Today 360. Why is this episode special? Let me explain. One of the goals of the Digital Health Today channel is to create a space where people can learn about great innovation that can improve the health of both individuals and entire populations.  Over the years, as I’ve been creating my own show, I’ve also had the opportunity to expand and serve the health community in other ways. Along with my colleagues at Mission Based Media, we’ve created other audio-first resources to share more information. For example, we created Health Podcast Network to showcase other high-quality, human-centered and evidence-based podcasts. Health Podcast Network now has about 100 different health podcasts and 13,000 episodes.  We also worked through the pandemic to add new shows to Digital Health Today such as the DTx Podcast with Eugene Borukhovich, where he dives into the nascent digital therapeutics industry. And, most recently, we launched a library of podcasts called Health Unmuted where we create and share short-format, narrated, audio stories to help people understand more about specific health conditions. We launched the proof-of-concept miniseries last year called COPD Podcast. In June we launched the 5-part miniseries about Alzheimer’s Disease, and this month, in July, we’ll launch a 7-part miniseries about Parkinson’s disease. Why am I explaining all this? Because all this work at the intersection of health and podcasting has given me a chance to experiment with different formats, styles, content and audiences, and it’s also made me realize that I love creating this show.   It’s also made me more aware than ever that there is so much more that needs to be shared.   So, in this special episode, as I fire up the recording studio and prepare some great conversations with guests over the coming weeks and months, I thought I’d stand aside and invite another podcaster who is doing some great work in an area that needs much more attention.   Georgie Kovacs is the founder and host of Fempower Health - the go-to resource for all things women’s health serving women, their providers, and companies looking to build and improve on products for women. Georgie is really open about her first-hand experience with infertility and endometriosis. With that experience, she was motivated to start a podcast - in the middle of COVID, and as a single parent. Now if that’s not passion, I don’t know what is. You can find her show, Fempower Health, on Health Podcast Network. In this special episode, Georgie spoke with Dr. Michal Elovitz. Dr. Elovitz is the Distinguished Professor in Women’s Health at the Perelman School of Medicine at the University of Pennsylvania and she’s also the Chief Medical Advisor at Mirvie, a company creating a personalized window into pregnancy health.   When it comes to women’s health, I’ve been astonished at the tremendous need for improvement, funding and resources, and at the same time, I’ve also seen some incredible innovation that is happening that needs more attention, awareness and funding! And despite the U.S. having the highest maternal mortality rate among developed countries, health risks in pregnancy health have remained understudied, underfunded, and underserved. Pregnancy complications such as preeclampsia, preterm birth and gestational diabetes impact 1 in 5 women, and with no accurate way to predict them before symptoms appear, both moms and babies are often in crisis mode when diagnosed in their third trimester.  In their conversation, Georgie and Dr. Elovitz explain one of those complications, preeclampsia, and explore how better screening can help. Let me know what you think of this episode. Drop me a line on Twitter or LinkedIn and let me know! More great episodes of DHT360 are on the way, so be sure to hit follow on your favorite podcast app.   Thanks for tuning in!

Technology is under the microscope, as are the behaviors of the people who develop and deploy it. As technology impacts virtually every aspect of society, it's use within the life sciences goes beyond traditional bioethical topics.  This creates a host of questions for people and businesses working at the forefront of health innovation. In this episode, hear Nick Bott, Global Head, Bioethics and Technology Ethics at Takeda as we discuss: What is being done to ensure that the decisions around the use of technology for our health and wellbeing are carefully considered and applied?  Whose job is it to address the ethical questions in the development of AI and ML algorithms?  How can life science companies lead the way in setting standards for ethical development? What can we learn from Tony Stark - otherwise known as Iron Man in the Marvel Cinematic Universe? What is a 'consequence scanning workshop'? What is the role of regulation in setting standards and principles? Episode Links and Resources: Learn More About Ethics and Compliance at Takeda Notre Dame-IBM Technology Ethics Lab Markkula Center for Applied Ethics at Santa Clara University About the Age of Ultron - a lesson in 'irresponsible innovation'? Hear the Coffee Talk about the Health Outcomes Observatory (H2O) Guest Host Links Connect with Nick Bott on LinkedIn Connect on Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Connect on Health Podcast Network: Browse Shows | Linkedin | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Roche Takeda

Guest host Sophie Park interviews health economist Jane Sarasohn-Kahn for this fast-paced discussion about women's health, social determinants of health and the 'she-cession' in the wake of the COVID-19 pandemic. We've seen the headlines during COVID-19: Rising caseloads. Millions of lives lost. Economic devastation. Schools closed. But these only tell part of the story. The impact of the pandemic on mental and physical health extends far beyond those that are directly infected with the disease. Delayed diagnosis, canceled or delayed treatment, loss of employment and the collision of home and professional responsibilities has had a tremendous and long-lasting impact. Join Jane Sarasohn-Kahn and guest host Sophie Park in this discussion about the affects of the pandemic. For more discussion about women's health, check out the video panel with Jane and Sonia Millsom, Chief Commercial Officer of Maven Clinic, on the September 9 Digital Health Forum. Episode Links and Resources: Connect with Jane Sarasohn-Kahn: Website | Twitter | LinkedIn | Attend Digital Health Forum: Website | LinkedIn | Twitter Tune into Episode 16 with Kate Ryder, founder of Maven Clinic Guest Host Links Twitter @sophiemariepark Linkedin: https://www.linkedin.com/in/sophiemariepark/ Connect on Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Connect on Health Podcast Network: Browse Shows | Linkedin | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Roche Takeda

Every day, tech companies and governments frame the conversation around the use of data. With the proliferation of smartphones and wearable devices, online shopping, and home voice assistants, we leave a digital footprint with almost everything we do. While our data can be crunched to drive better insights on listening habits, activity levels, and consumer preferences. There's also a far more important application for our data: to improve human lives and health outcomes.  In this coffee talk, we explore how leaders in the pharmaceutical industry are working with people, policy makers and providers to create solutions that will usher in a new era of healthcare solutions and services. This Coffee Talk is created with support from Takeda. Guest Links and Resources: Connect with Meni Styliadou: LinkedIn Connect with Takeda: Website | Twitter | LinkedIn Connect with H2O: Website | Twitter | LinkedIn | YouTube European Patient Forum: Website Innovative Medicines Initiative: Website | Twitter | LinkedIn | YouTube Host Links Connect with Dan: Twitter | LinkedIn Connect on Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Connect on Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

The pandemic has illustrated how Social Determinants of Health (SDOH) can impact the spread of disease, access to vaccines and the levels of trust in and utilization of basic health services. Beyond the focus on SDOH by politicians, advocacy, groups, and charitable organizations, there are private and public commercial organizations that make it a priority to find and fund solutions that address the social and cultural barriers that reduce or limit access to care. One of those organizations is Bayer. In this conversation with Dominick Kennerson, Global Head of Bayer G4A, we discuss how equity, access and sustainability help set the course for their investment strategy. This Coffee Talk is created in partnership with our Sponsor, Bayer G4A. This year Bayer G4A is looking for companies creating solutions to 5 key challenges including oncology, radiology, mental health, women's health and cardio metabolic and renal diseases.   The Bayer G4A program is open to companies from pre-seed stage to Series A, and even more advanced companies with traction in the market. Apply to be a part of Bayer G4A here, and tell them you heard about it on Digital Health Today. The deadline to apply is June 20, 2021. Guest Links and Resources: Connect with Dom Kennerson: Twitter | LinkedIn Connect with Bayer G4A: Website | Twitter | LinkedIn | YouTube World Health Organization - Website | Constitution Host Links Connect with Dan: Twitter | Linkedin Connect on Digital Health Today: Browse Episodes | Twitter | Linkedin | Facebook | Instagram Connect on Health Podcast Network: Browse Shows | Linkedin | Twitter | Facebook | Instagram

Dr. David E Albert is a physician, engineer, inventor and serial entrepreneur, and he's the founder and Chief Medical Officer of Alivecor. Dr. Albert has developed life-saving technologies and products for more than 30 years, and he's turned a number of those inventions into tech startups, even before it was a trendy thing to do. Each year, over 20,000 students enrolled in medical schools across the US. Over 600,000 businesses are started each year in the US, and nearly half fail within five years; two-thirds fail within 10 years. So why do people who are on a path to a successful career in medicine decide to become entrepreneurs? Dr. Albert says that "a lot of people go into medicine because it's not very risky. And so there's a real juxtaposition between those people who go into medicine because it's a secure professional lifestyle, and being an entrepreneur." Back in January, 2011, Dr. Albert posted a four minute YouTube video showing how to turn an apple iPhone 4 into a wireless clinical quality cardiac event recorder. It's called AliveCor, and it looked like magic. Ten years later, the AliveCor company continues to grow and expand. Tune into this special episode as we highlight the twists of fate and deliberate decisions that shaped Dr. Albert's career, and hear how his work and companies continue to make a lasting impact in the delivery of care. Guest Links and Resources: Connect with Dr. Dave Albert: Twitter | LinkedIn | Connect with AliveCor: Website | Twitter | LinkedIn | YouTube Dr. Albert's 2011 YouTube video showing the AliveCor ECG Host Links Twitter @healthtechdan Linkedin: https://www.linkedin.com/in/dankendall/ Connect on Digital Health Today: Browse Episodes | Twitter | Linkedin | Facebook | Instagram Connect on Health Podcast Network: Browse Shows | Linkedin | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Roche Takeda

In this episode, we dive into a topic that is very close to my heart: improving the lives of people with diabetes. You've certainly heard Kodak mentioned as a good example of how companies should *not* manage product development. A company that was once a household name is now known for missing out on the move to digital cameras. For as long as business has existed, there are examples of companies that didn't move with the times - and we're not just talking about steam trains and pocket watches. There are thousands of case studies from the modern era that can teach important business lessons; lessons about things we should do, and lessons about things we shouldn't. As the number of people with diabetes continues to climb globally, we see businesses working hard to adapt to the new and changing expectations of providers, employers and patients. Increasingly in healthcare, the innovation isn't just about a new technology or innovation. It's about creating sustainable business models that engage stakeholders across the value chain. To understand more about the internal and external factors and decisions that drive innovation, I invited Adam Berman to the show. Adam is Director of Franchise Marketing at Roche Diabetes Care. He has over 15 years of experience in marketing and business leadership primarily in the diabetes category.  In this episode, we explore diabetes as a use-case for taking bold steps to deliver better outcomes and experiences. We explore the capabilities of new digital solutions that Roche has developed, and the decisions that have led to their development. Note: Although Roche is a sponsor of the Digital Health Today platform, this episode is not a sponsored episode. I asked to interview Adam purely based on my professional and personal interests in gaining a better understanding of how Roche is driving digital solutions for better care, and to discuss what companies can and should do to succeed. Hope you enjoy it. Guest's Links and Resources: Connect with Adam Berman: LinkedIn Roche Diabetes Care Platform Roche Diabetes Health Connection,  Sulli the Diabetes Guru - Alexa Skill for managing diabetes MySugr Host Links Twitter @healthtechdan Linkedin: https://www.linkedin.com/in/dankendall/ Connect on Digital Health Today: Browse Episodes | Twitter | Linkedin | Facebook | Instagram Connect on Health Podcast Network: Browse Shows | Linkedin | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Roche Takeda Learn more about your ad choices. Visit megaphone.fm/adchoices

"In this episode, I'm excited to introduce you to yet another outstanding health innovation leader who is hosting another new show on Digital Health Today. His degrees are in engineering and business, and he is a writer, entrepreneur, investor, and advisor. He is a truly multi-talented person and I'm pleased to also call him a friend. I'm honored to introduce the host of the new Asia Pacific Edition of Digital Health Today, Tony Estrella. ~ Dan Kendall, Founder of Digital Health Today Links and Resources: Connect with Tony Estrella: Twitter | LinkedIn | Personal Website Connect with Taliossa Read Tony's Book: Comatose FutureProofing Healthcare Full Whitepaper, Summary and Video: A Vision for Asia Pacific in 2050  Connect on Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Connect on Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Special thanks to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode, I have the pleasure of introducing you to one of the health sectors leading innovators, and probably one of the best known and, dare I say it, most loved, leaders I’ve had the pleasure of knowing in my 20 plus years working in healthcare: Eugene Borukhovich. He’s a serial intra- and entrepreneur, executive, venture builder, speaker & board advisor with a focus in digital health. He’s also the Chairman and Founding Board Member at YourCoach.Health and founder of Initium Impact Ventures.  Prior to YourCoach, Eugene served as Global Head of Digital Health at Bayer. He has also co-founded and sold a doctor rating startup and a consulting company. Eugene recently relocated to Barcelona where he enjoys running, writing, traveling and spending time with his family. Be sure to subscribe to Eugene's new show on Digital Health Today focused on Digital Therapeutics. Links and Resources: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter HealthXL: Website | Twitter | Join an Event Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode, I have the pleasure of introducing you to one of the health sectors leading innovators, and probably one of the best known and, dare I say it, most loved, leaders I’ve had the pleasure of knowing in my 20 plus years working in healthcare: Eugene Borukhovich. He’s a serial intra- and entrepreneur, executive, venture builder, speaker & board advisor with a focus in digital health. He’s also the Chairman and Founding Board Member at YourCoach.Health and founder of Initium Impact Ventures.  Prior to YourCoach, Eugene served as Global Head of Digital Health at Bayer. He has also co-founded and sold a doctor rating startup and a consulting company. Eugene recently relocated to Barcelona where he enjoys running, writing, traveling and spending time with his family. Be sure to subscribe to Eugene's new show on Digital Health Today focused on Digital Therapeutics. Links and Resources: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter HealthXL: Website | Twitter | Join an Event Subscribe to Exits & Outcomes Brian Dolan: Twitter | LinkedIn Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Cedars-Sinai Accelerator Takeda Roche Learn more about your ad choices. Visit megaphone.fm/adchoices

Welcome back to Digital Health Today, the place to be to get the insights of leaders making the healthcare of tomorrow, available today. I’m your host, Dan Kendall and this is a Coffee Talk. Coffee Talks are opportunities to hear directly from the leaders of organizations that make our platform possible, and to keep up to date on the pivots and progress of the evolving digital health ecosystem. In this episode I welcome two executives from Bayer G4A. Bayer G4A has been a longtime sponsor of Digital Health Today. I caught up with Dominick Kennerson, Global Head G4A, Digital Health Partnerships at Bayer Pharmaceuticals. I also spoke with Sophie Park. Sophie is a veteran guest of the Digital Health Today program, and the Chief Strategist for Bayer G4A Partnerships. Dominick and Sophie are American based in Berlin, Germany, and Dominick shared how a chance meeting at a Washington, D.C. bar began his path to a career in Europe. We also spoke about the impact of COVID-19 on the Bayer organization, and how it has changed the expectations and opportunities for companies of all sizes working to make a dent in healthcare. He also traces the early use of the term 'digital health' back to his time at Revolution Health. Earlier this year, Bayer G4A had a call for applications. They are looking for innovative companies that are ready to make a difference in specific key challenge areas. After months of hard work and vetting all the applicants, they’re about to announce the finalists for this year’s Bayer G4A Program. While we don’t know the companies they’ve selected at the time of this recording, they will be announced very soon at a global virtual event taking place at 11am Eastern on Wednesday, November 18, 2020. If you’re listening to this episode on or before Nov 18, click here to register to attend. If you’re tuning in on November 19 or later, scroll down to find names and links to the companies that have been accepted.  Now without further ado, let’s tune into the conversation with Dominick Kennerson and Sophie Park Welcome to the 2020 G4A Class! And the winners are.... Not announced yet! Click here to register for the virtual event to be held at 11am Eastern, 5pm CET, on Wednesday November 18, 2020 Connect on Digital Health Today: Browse Episodes | Twitter | Linkedin | Facebook | Instagram Connect on Health Podcast Network: Browse Shows | Linkedin | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Almirall Digital Garden Cedars-Sinai Accelerator University of Chicago - Master of Science in Biomedical Informatics Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode I welcome two executives from Bayer G4A. Bayer G4A has been a longtime sponsor of Digital Health Today. I caught up with Dominick Kennerson, Global Head G4A, Digital Health Partnerships at Bayer Pharmaceuticals. I also spoke with Sophie Park. Sophie is a veteran guest on the Digital Health Today program, and the Chief Strategist for Bayer G4A Partnerships. Dominick shared how a chance meeting at a Washington, D.C. bar began his path to a career in Europe. We also spoke about the impact of COVID-19 on the Bayer organization, and how it has changed the expectations and opportunities for companies of all sizes working to make a dent in healthcare. He also traces the early use of the term 'digital health' back to his time at Revolution Health. Agents of Change - A Virtual Digital Health Forum: Earlier this year, Bayer G4A had a call for applications. They are looking for innovative companies that are ready to make a difference in specific key challenge areas. After months of hard work and vetting all the applicants, they’re about to announce the finalists for this year’s Bayer G4A Program. While we don’t know the companies they’ve selected at the time of this recording, they will be announced very soon at a global virtual event taking place at 11am Eastern (5PM CET) on Wednesday, November 18, 2020. So, if you’re listening to this episode on or before Nov 18, click here to register to attend.  And - if you missed it, scroll down to find names and links to the companies that have been accepted.  Now without further ado, let’s tune into the conversation with Dominick Kennerson and Sophie Park View Transcript Meet the 2020 G4A Partners in the G4A Program! Caria - Manage menopause with confidence. Decipher Biosciences - A commercial-stage precision oncology company committed to improving patient care Sweetch - A clinically validated, personalized, AI disease management optimization platform. Oncare - Connects you with your care team, so that they can digitally support you in your therapy  Elly - Daily motivation and support for people living with a chronic condition Digital Health Today is made possible by the support of our sponsors. Thank you to: Bayer G4A Almirall Digital Garden Cedars-Sinai Accelerator University of Chicago - Master of Science in Biomedical Informatics Connect on Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Connect on Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram

Imagine this: You’re the founder of a digital health startup. You’ve been carefully selected and invited to participate in a brand new accelerator in Barcelona. At the start of the year, you say goodbye to your friends and family, you find a place in Barcelona to call home, and you focus on growing your business with the mentorship and support of one of the world’s leading pharmaceutical companies.  And then, COVID-19 happens.  How does that impact your strategy? How will it affect your success? And will the fight you wage for survival have an impact the healthcare sector at large? In this Coffee Talk we speak with Carlos Gallardo, the CEO and Founder of CG Health Ventures and a board member at Almirall. He has invested personally in about a dozen companies - including Washington DC-based Babyscripts, whose co-founder Juan Pablo Segura was a guest on episode 67. Carlos is based in Barcelona, and he often takes an active role in helping his companies develop their product market fit.  Background: At the end of 2019, Almirall selected and invited 4 companies to participate in their first cohort - aka "First Harvest" - at the Digital Garden in beautiful Barcelona. Like all things in 2020, the plans had to change to adapt to our new reality. In the face of this global crisis, the startups have embraced and benefited from opportunities that no one predicted in January. And Almirall itself has benefited from the Digital Garden as well. In October 2020, Almirall launched their call for their second cohort - or, as they like to call it - their "Second Harvest."  Find out more by visiting our website digitalhealthtoday.com/digitalgarden. Applications are open until October 31, 2020, so don’t delay. Links and Resources: Apply to Almirall Digital Garden - Deadline is Oct 31, 2020! Connect with Carlos Gallardo: LinkedIn | CG Health Ventures Digital Garden's First Harvest: Haut.ai Derma2Go Uvisio Intrepida Analytics Connect on Digital Health Today: Browse Episodes | Twitter | Linkedin | Facebook | Instagram Connect on Health Podcast Network: Browse Shows | Linkedin | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Almirall Digital Garden Bayer G4A Cedars-Sinai Accelerator Medable University of Chicago - Master of Science in Biomedical Informatics Learn more about your ad choices. Visit megaphone.fm/adchoices

Imagine this: You’re the founder of a digital health startup. You’ve been carefully selected and invited to participate in a brand new accelerator in Barcelona. At the start of the year, you say goodbye to your friends and family, you find a place in Barcelona to call home, and you focus on growing your business with the mentorship and support of one of the world’s leading pharmaceutical companies.  And then, COVID-19 happens.  How does that impact your strategy? How will it affect your success? And will the fight you wage for survival have an impact the healthcare sector at large? In this Coffee Talk we speak with Carlos Gallardo, the CEO and Founder of CG Health Ventures and a board member at Almirall. He has invested personally in about a dozen companies - including Washington DC-based Babyscripts, whose co-founder Juan Pablo Segura was a guest on episode 67. Carlos is based in Barcelona, and he often takes an active role in helping his companies develop their product market fit.  Background: At the end of 2019, Almirall selected and invited 4 companies to participate in their first cohort - aka "First Harvest" - at the Digital Garden in beautiful Barcelona. Like all things in 2020, the plans had to change to adapt to our new reality. In the face of this global crisis, the startups have embraced and benefited from opportunities that no one predicted in January. And Almirall itself has benefited from the Digital Garden as well. In October 2020, Almirall launched their call for their second cohort - or, as they like to call it - their "Second Harvest."  Find out more by visiting the Almirall Digital Garden Website. Applications are open until October 31, 2020, so don’t delay. View transcript Links and Resources: Apply to Almirall Digital Garden - Deadline is Oct 31, 2020! Connect with Carlos Gallardo: LinkedIn | CG Health Ventures Digital Garden's First Harvest: Haut.ai Derma2Go Uvisio Intrepida Analytics Connect on Digital Health Today: Browse Episodes | Twitter | Linkedin | Facebook | Instagram Connect on Health Podcast Network: Browse Shows | Linkedin | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Almirall Digital Garden Bayer G4A Cedars-Sinai Accelerator Medable University of Chicago - Master of Science in Biomedical Informatics Learn more about your ad choices. Visit megaphone.fm/adchoices

If you’ve been tuned into nearly any news channel recently, you’ve probably seen the announcement by Akili about the clearance they announced on June 15 for their product EndeavorRX. It is the first prescription treatment delivered through a video game which is designed to treat Pediatric ADHD. This was quickly followed by an announcement on June 23, 2020 of their CE Mark certification. Like many of you I’ve been tracking the work and progress at Akili for a long time, and I was excited to hear about this important milestone, and when the Akili team contacted me to see if I wanted to have a closer look at and try Endeavor RX, I couldn’t resist. I’ve downloaded it to my iPad and gave it a try, and I’m impressed. I can’t speak to the clinical aspects of the product, but based on the standards and expectations that we have from consumer focused products, this was a great experience. It’s well-designed, was easy to get set up, and it uses a great combination of graphics and sounds to engage the player. I love the way they are positioning this with the simple and memorable tagline - “Play your medicine”. That sort of sums it up. To learn more about the importance of this milestone and go a little deeper behind the headlines, I grabbed a few minutes to connect with Eddie Martucci, the Co-Founder and CEO at Akili Interactive Labs. Eddie shares what the recent FDA clearance and CE Mark approval mean to the business. We also discuss the commercialization plans, the volume and value of data created by digital tools, and how Digital Medicine and Digital Therapeutics will continue to transform the relationship between companies and people. Links and Resources: Connect with Eddie Martucci, PhD: Twitter | LinkedIn Connect with Akili Interactive Labs: Website | Twitter | LinkedIn Read the Press Release for FDA Clearance Read the Press Release for CE Mark Certification Lancet Digital Health Journal summary for STARS-ADHD Download the App Connect on Digital Health Today: Browse Episodes | Twitter | Linkedin | Facebook | Instagram Connect on Health Podcast Network: Browse Shows | Linkedin | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Almirall Digital Garden Bayer G4A Cedars-Sinai Accelerator Medable University of Chicago - Master of Science in Biomedical Informatics Learn more about your ad choices. Visit megaphone.fm/adchoices

If you’ve been tuned into nearly any news channel recently, you’ve probably seen the announcement by Akili about the clearance they announced on June 15 for their product EndeavorRX. It is the first prescription treatment delivered through a video game which is designed to treat Pediatric ADHD. This was quickly followed by an announcement on June 23, 2020 of their CE Mark certification. Like many of you I’ve been tracking the work and progress at Akili for a long time, and I was excited to hear about this important milestone, and when the Akili team contacted me to see if I wanted to have a closer look at and try Endeavor RX, I couldn’t resist. I’ve downloaded it to my iPad and gave it a try, and I’m impressed. I can’t speak to the clinical aspects of the product, but based on the standards and expectations that we have from consumer focused products, this was a great experience. It’s well-designed, was easy to get set up, and it uses a great combination of graphics and sounds to engage the player. I love the way they are positioning this with the simple and memorable tagline - “Play your medicine”. That sort of sums it up. To learn more about the importance of this milestone and go a little deeper behind the headlines, I grabbed a few minutes to connect with Eddie Martucci, the Co-Founder and CEO at Akili Interactive Labs. Eddie shares what the recent FDA clearance and CE Mark approval mean to the business. We also discuss the commercialization plans, the volume and value of data created by digital tools, and how Digital Medicine and Digital Therapeutics will continue to transform the relationship between companies and people. View transcript Links and Resources: Connect with Eddie Martucci, PhD: Twitter | LinkedIn Connect with Akili Interactive Labs: Website | Twitter | LinkedIn Read the Press Release for FDA Clearance Read the Press Release for CE Mark Certification Lancet Digital Health Journal summary for STARS-ADHD Download the App Connect on Digital Health Today: Browse Episodes | Twitter | Linkedin | Facebook | Instagram Connect on Health Podcast Network: Browse Shows | Linkedin | Twitter | Facebook | Instagram Digital Health Today is made possible by the support of our sponsors. Thank you to: Almirall Digital Garden Bayer G4A Cedars-Sinai Accelerator Medable University of Chicago - Master of Science in Biomedical Informatics

For this special Coffee Talk, I invited Sophie Park, Chief Strategist for Bayer G4A Partnerships to discuss the opportunities for later stage startups to grow and partner with a global pharma company. The Bayer G4A program has continued to grow and succeed since 2013, and it has evolved to adapt to changing market forces, new business priorities and the unprecedented acceleration of innovation that has taken place at the intersection of health and technology.  One of the challenges when an organization has a long history of success like that is that people begin to automatically associate what they knew about the program in previous years, and then overlay that to make presumptions about what the program is like this year.   For example - a lot of people think that G4A is simply an accelerator for early stage startups.  In actual fact, they also have a very powerful partnership program which is designed to attract companies that can participate in joint ventures, commercial partnerships or even majority investments.   To dispel some of these myths and to give more insights on the progress and success of the G4A program and family. Links and Resources: Learn more about Bayer G4A: Web | Twitter Connect on Digital Health Today: Browse Episodes | Twitter | Linkedin | Facebook | Instagram Connect on Health Podcast Network: Browse Shows | Linkedin | Twitter | Facebook | Instagram   Digital Health Today is made possible by the support of our sponsors. Thank you to University of Chicago - Master of Science in Biomedical Informatics Almirall Digital Garden Bayer G4A Cedars-Sinai Accelerator Medable Learn more about your ad choices. Visit megaphone.fm/adchoices